Philips patient monitors with integrated Masimo measurements work together to provide you with continuous visibility to core vital signs and advanced parameters at the point of care. So you can confidently provide the best patient experience possible – no matter where care takes place.
Let us show you how Philips monitors and Masimo measurements work together to deliver greater visibility and deeper insight at every stage of the care journey.
you can know more
and respond sooner
Philips IntelliVue and Masimo Horizon Trends Horizon Trends are built into many Philips IntelliVue monitors and provide graphical representation of vital sign changes to make deviations easier to notice.
Masimo rainbow SET® parameters As part of the Philips / Masimo partnership, customers have access to Masimo’s noninvasive monitoring technologies in Philips IntelliVue monitors, including Masimo rainbow SET technology. The rainbow SET technology provides customers the option to purchase advance clinical measurement parameters.
Common measurement parameters SpO2 - measure of oxygen saturation even through motion and low perfusion SpHb1 - provides continuous visibility to changes – or lack of changes – in hemoglobin levels between invasive blood samples PVi - measure of the dynamic changes in the Perfusion Index (PERF) that occur during one or more respiratory cycles
SPO2 noninvasive oxygen saturation SpHb noninvasive continuous hemoglobin PVi Pleth Variability index Pi PERF Perfusion index SpOC noninvasive oxygen content SpMet noninvasive methemoglobin
Horizon trends clearly indicate timely changes in patient condition – to aid you to quickly identify meaningful clinical deviations and take appropriate actions.
Discover how Philips Capital can help you finance your healthcare operations.
Masimo clinical claims are referenced on this web page. All studies available at www.masimo.com/evidence/featured-studies/feature/ (1) SpHb** monitoring is not intended to replace lab testing. Blood samples should be analyzed by lab instruments prior to clinical decision making. (2) (3) Awada WN et al J Clin Mon it Comput. DOI 10.1007/s10877-015-9660-4. *Study Protocol: In each group, if researchers noted SpHb trended downward below 10 g/dl, a red blood cell transfusion was started and continued until SpHb trended upward above 10 g/dl. The transfusion threshold of 10 g/dl was predetermined by the study protocol and may not be appropriate for all patients. Blood sampling was the same for the control and test group.
You are about to visit a Philips global content page
Continue